FT Options’s Kite Pharma, Inc. KITE Stock Holding History

FT Options’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$1.32M	Buy	103,200 +77,900	+308%	+$10.9M	2%	13
2017 Q2	$604K	Sell	25,300 -56,400	-69%	-$4.6M	1.04%	26
2017 Q1	$1.29M	Buy	81,700 +61,700	+309%	+$3.82M	1.69%	12
2016 Q4	$109K	Buy	20,000 +17,100	+590%	+$839K	0.13%	99
2016 Q3	$1K	Buy	+2,900	New	+$162K	﹤0.01%	360
2016 Q2	–	Sell	-20,100	Closed	-$6K	–	441
2016 Q1	$6K	Buy	+20,100	New	+$974K	0.01%	265

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FT Options's KITE Position: Q4 2016 in Review

FT Options sold out of Kite Pharma, Inc. (KITE) in Q4 2016, closing a stake of 21,134 shares — an estimated $1.04M sold.

FT Options first reported a position in KITE in Q3 2016 and held it in 1 quarter. The position peaked at $1.18M in Q3 2016. 184 funds tracked by Wall St. Rank hold KITE as of Q4 2016.

FT Options reported no remaining Kite Pharma, Inc. position as of Q4 2016 after selling out during the quarter.
FT Options sold 21,134 Kite Pharma, Inc. shares in Q4 2016, an estimated $1.04M.
FT Options first reported a position in Kite Pharma, Inc. in Q3 2016 and held it in 1 quarter.
FT Options's Kite Pharma, Inc. position peaked at $1.18M in Q3 2016.
184 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2016.

Based on FT Options's 13F filing for Q4 2016, filed 10 Feb 2017.